Cargando…

Acid-suppressive therapy among infants and risk of anemia at 12 months of age

OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sulb, Ahmad, Al-Najjar, Rawan, Maghnam, Rama, Ashhab, Ashraf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465608/
https://www.ncbi.nlm.nih.gov/pubmed/36105547
http://dx.doi.org/10.1177/20503121221123117
_version_ 1784787835944960000
author Abu-Sulb, Ahmad
Al-Najjar, Rawan
Maghnam, Rama
Ashhab, Ashraf
author_facet Abu-Sulb, Ahmad
Al-Najjar, Rawan
Maghnam, Rama
Ashhab, Ashraf
author_sort Abu-Sulb, Ahmad
collection PubMed
description OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. METHODS: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t-test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. RESULTS: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. CONCLUSION: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed.
format Online
Article
Text
id pubmed-9465608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94656082022-09-13 Acid-suppressive therapy among infants and risk of anemia at 12 months of age Abu-Sulb, Ahmad Al-Najjar, Rawan Maghnam, Rama Ashhab, Ashraf SAGE Open Med Original Research Article OBJECTIVES: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. METHODS: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t-test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. RESULTS: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. CONCLUSION: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed. SAGE Publications 2022-09-08 /pmc/articles/PMC9465608/ /pubmed/36105547 http://dx.doi.org/10.1177/20503121221123117 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Abu-Sulb, Ahmad
Al-Najjar, Rawan
Maghnam, Rama
Ashhab, Ashraf
Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_full Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_fullStr Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_full_unstemmed Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_short Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_sort acid-suppressive therapy among infants and risk of anemia at 12 months of age
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465608/
https://www.ncbi.nlm.nih.gov/pubmed/36105547
http://dx.doi.org/10.1177/20503121221123117
work_keys_str_mv AT abusulbahmad acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT alnajjarrawan acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT maghnamrama acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT ashhabashraf acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage